---
figid: PMC8836162__ijms-23-01679-g004
figtitle: EphrinB2–EphB4 Signaling in Neurooncological Disease
organisms:
- NA
pmcid: PMC8836162
filename: ijms-23-01679-g004.jpg
figlink: /pmc/articles/PMC8836162/figure/ijms-23-01679-f004/
number: F4
caption: EphB4 resistance mechanisms towards antiangiogenic treatment in glioma. EphrinB2
  expression in tumors is reduced after antiangiogenic treatment, arbitrated by means
  of elevated levels of hypoxia-inducible factor (HIF-1α) and zinc finger E-box-binding
  homeobox 2 (ZEB2) []. Among other effects, this pathway enhances tumor invasiveness.
  In forward signaling, EphB4 controls the activation of the EGF receptor via the
  Wnt/beta-catenin signaling pathway. The EGF receptor phosphorylates phosphoinositide
  phospholipase C-gamma-1 (PLC-γ1), which was found to drive gene expression changes
  in Sunitinib resistant glioma []. PLC-γ1 phosphorylation increases tumor invasiveness
  in other tumor entities. In the endothe-lium, antiangiogenic therapy blocks VEGFR–EphrinB2
  dimerization and Delta-Like Canonical Notch Ligand 4 (DLL4) activa-tion []. EphB4
  is progressively expressed in Bevacizumab resistant blood vessels and regulates
  DLL4/Notch proportions via cerebral cavernous malformation 3 (CCM3) [,]. Endothelial
  EphB4 overexpression forms large, treatment insensitive vessels expressing increased
  amounts of TIE2 and ANG1 and decreased amounts of ANG2 []. Additionally, it protects
  cells from apoptosis possibly through the PI3K-AKT-ERK pathway [].
papertitle: EphrinB2–EphB4 Signaling in Neurooncological Disease.
reftext: Andras Piffko, et al. Int J Mol Sci. 2022 Feb;23(3):1679.
year: '2022'
doi: 10.3390/ijms23031679
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords: EphB4 | ephrinB2 | metastasis | glioblastoma | glioma | bone | brain metastasis
  | spinal metastasis | neurooncology | bone metastasis
automl_pathway: 0.5839873
figid_alias: PMC8836162__F4
figtype: Figure
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC8836162__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8836162__ijms-23-01679-g004.html
  '@type': Dataset
  description: EphB4 resistance mechanisms towards antiangiogenic treatment in glioma.
    EphrinB2 expression in tumors is reduced after antiangiogenic treatment, arbitrated
    by means of elevated levels of hypoxia-inducible factor (HIF-1α) and zinc finger
    E-box-binding homeobox 2 (ZEB2) []. Among other effects, this pathway enhances
    tumor invasiveness. In forward signaling, EphB4 controls the activation of the
    EGF receptor via the Wnt/beta-catenin signaling pathway. The EGF receptor phosphorylates
    phosphoinositide phospholipase C-gamma-1 (PLC-γ1), which was found to drive gene
    expression changes in Sunitinib resistant glioma []. PLC-γ1 phosphorylation increases
    tumor invasiveness in other tumor entities. In the endothe-lium, antiangiogenic
    therapy blocks VEGFR–EphrinB2 dimerization and Delta-Like Canonical Notch Ligand
    4 (DLL4) activa-tion []. EphB4 is progressively expressed in Bevacizumab resistant
    blood vessels and regulates DLL4/Notch proportions via cerebral cavernous malformation
    3 (CCM3) [,]. Endothelial EphB4 overexpression forms large, treatment insensitive
    vessels expressing increased amounts of TIE2 and ANG1 and decreased amounts of
    ANG2 []. Additionally, it protects cells from apoptosis possibly through the PI3K-AKT-ERK
    pathway [].
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KDR
  - FLT1
  - FLT4
  - ANGPT2
  - VPS51
  - VEGFA
  - ANGPT1
  - TM7SF2
  - EGFR
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - DLL4
  - TEK
  - PDCD10
  - EPHB2
  - MAPK1
  - MAPK3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - Pvr
  - E(spl)malpha-BFM
  - Pvf1
  - Egfr
  - .na.character
  - Ccm3
  - Erk7
  - rl
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
---
